Sfoglia per AUTORE
DI DONATO S
Collezione AOU San Luigi di Orbassano

  

Items : 3

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. in The Lancet. Oncology

2024
AOU San Luigi di Orbassano

Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; et alii...

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. in BMC cancer / BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

De Vita F; Ciuffreda L; Basso M; Catalano V; Bracarda S; Verusio C; Maiello E; Cinieri S; Giuliani F; Tassinari D; Frassineti GL; Spallanzani A; Bonetti A; Tortora G; Scagliotti G; Pinotti G; Tomasello G; Bertolini A; Zaniboni A; Longarini R; Luporini AG; Rimassa L; Di Costanzo F; Cardellino GG; Scartozzi M; Berardi R; Di Donato S; Lonardi S; Tamberi S; et alii...

Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial in Journal of Clinical Oncology

2019
AOU San Luigi di Orbassano

Morano F; Niger M; Corallo S; Lonardi S; Tamberi S; Di Donato S; Giommoni E; Giuliani F; Frassineti GL; Tomasello G; De Vita F; Cardellino GG; Pinotti G; Brizzi MP; Rimassa L; Scartozzi M; Berardi R; De Braud FG; Pietrantonio F; Di Bartolomeo M;